 |
Amgen Issues Statement On Outcomes Of Advisory Committee For Reproductive Health Drugs (ACRHD) Meeting
|
| Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast cancer.
|
| 8/15/2009
1:00 AM |
|
|
Financial Coaching Help For Patients Fighting Cancer
|
| During this tough economy, the financial burden on cancer patients can be especially trying. Balancing everyday expenses with care-related costs and, for some, income loss, can result in significant financial stress. Recognizing these challenges, Dana-Farber Cancer Institute has teamed up with the Financial Planning Association of Massachusetts to offer free, individual financial coaching services to its patients and their caregivers. It is one of the nation's first such programs.
|
| 8/15/2009
1:00 AM |
|
|
Possible Genetic Links Between Environmental Toxins And Multiple Myeloma Suggested By New Study
|
| The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affect production of blood cells and can damage bone.
|
| 8/15/2009
12:00 AM |
|
|
Raising The Alarm When DNA Goes Bad
|
| Our genome is constantly under attack from things like UV light and toxins, which can damage or even break DNA strands and ultimately lead to cancer and other diseases. Scientists have known for a long time that when DNA is damaged, a key enzyme sets off a cellular 'alarm bell' to alert the cell to start the repair process, but until recently little was known about how the cell detects and responds to this alarm.
|
| 8/15/2009
12:00 AM |
|
|
Scientists Develop Way To Seek And Destroy Cancer Stem Cells
|
| Scientists in the US have developed a way of identifying chemicals that specifically seek and destroy cancer stem cells and showed it worked by finding a compound that was toxic only to breast cancer stem cells in mice.
|
| 8/14/2009
8:00 AM |
|
|
First Compound That Specifically Kills Cancer Stem Cells Found
|
| The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.
|
| 8/14/2009
3:00 AM |
|
|
Questions Over Timely Investigation Of "alarm Symptoms"
|
| Many patients presenting to their doctor with certain alarm symptoms, such as difficulty swallowing or rectal bleeding, may not be receiving a timely diagnosis, finds a study published on bmj.com today. Certain symptoms, such as blood in the urine (haematuria), coughing up blood (haemoptysis), difficulty swallowing (dysphagia), and rectal bleeding, are generally regarded as "red flags" because of their association with serious disease.
|
| 8/14/2009
1:00 AM |
|
|
Clinical Trial At The Cancer Institute Of New Jersey Focuses On New Immune Therapy In Combination With Standard Treatment For Kidney Cancer
|
| Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient's relative. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
|
| 8/14/2009
1:00 AM |
|
|
OncoGenex Expands Clinical Development Of OGX-427 With A Phase 1 Clinical Trial In Bladder Cancer
|
| OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1 trial of OGX-427 administered systemically in patients with various solid tumors.
|
| 8/14/2009
1:00 AM |
|
|
Interventional Radiology Treatment For Uterine Fibroids: Safe, Nonsurgical Option
|
| Uterine fibroid embolization--a minimally invasive interventional radiology treatment for women that cuts off blood flow to painful fibroids to kill the tumors--is highlighted as an appropriate treatment for women in a Clinical Therapeutics article in the Aug. 13 issue of the New England Journal of Medicine. "UFE (also called uterine artery embolization or UAE) is a safe, effective and minimally invasive option for women to consider.
|
| 8/14/2009
1:00 AM |
|
|
Protein Plays Unexpected Role Protecting Chromosome Tips
|
| A protein specialist that opens the genomic door for DNA repair and gene expression also turns out to be a multi-tasking workhorse that protects the tips of chromosomes and dabbles in a protein-destruction complex, a team lead by researchers at The University of Texas M. D. Anderson Cancer Center reports in the Aug. 13 edition of Molecular Cell.
|
| 8/14/2009
1:00 AM |
|
|
Emory Named To Nationwide NCI Chemical Biology Consortium By National Cancer Institute
|
| Emory University's Chemical Biology Discovery Center has been selected by SAIC-Frederick, Inc. (SAIC-F) to be part of an 11-member national consortium aimed at accelerating the discovery and development of new and innovative, targeted cancer therapies. SAIC-F is the prime contractor to the National Cancer Institute at Frederick (NCI-Frederick).
|
| 8/14/2009
12:00 AM |
|
|
"Alarm Symptoms": Timely Investigation And Diagnosis
|
| A study just published on bmj.com reports that many patients presenting to their doctor with certain alarm symptoms, such as difficulty swallowing or rectal bleeding, may not be receiving opportune diagnosis.
|
| 8/14/2009
12:00 AM |
|
|
Colorado State University Veterinarian Receives Lifetime Recognition For Research
|
| The American Veterinary Medical Association recently honored Colorado State University veterinarian Dr. Anthony Simon Turner with the Lifetime Excellence in Research Award. The award recognizes achievement in veterinary research. Turner has been a member of the College of Veterinary Medicine and Biomedical Sciences faculty since 1977.
|
| 8/13/2009
11:00 AM |
|
|
US Cancer Deaths Falling Steadily
|
| The number of deaths due to cancer in the United States has fallen steadily over the last 30 years, with the steepest declines occurring among the younger age groups, said researchers, who suggested improvements in prevention, detection and treatment are largely responsible for the gains across the board, but because of the way disease statistics are presented, most people remain unaware of this good news.
|
| 8/13/2009
9:00 AM |
|
|
Cancer Mortality Rates Experience Steady Decline, US
|
| The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.
|
| 8/13/2009
8:00 AM |
|
|
Fighting Cancer With Anti-Psychotic Drugs
|
| The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers. A preliminary finding in the current online issue of the International Journal of Cancer reports that the anti-psychotic drug, pimozide, kills lung, breast and brain cancer cells in in-vitro laboratory experiments.
|
| 8/13/2009
4:00 AM |
|
|
Potential New Avenue To Attack Cancer Identified By Researchers
|
| New insight into how human cells reproduce, published by cancer researchers at Michigan State University and the Van Andel Research Institute in Grand Rapids, could help scientists move closer to finding an "off switch" for cancer. Cancer cells divide uncontrollably and can move from one part of the body to another.
|
| 8/13/2009
3:00 AM |
|
|
Can Sequential TACE And Cryosurgery Improve Survival Times For Patients With HCC?
|
| Hepatocellular carcinoma (HCC)--a liver cancer--is recognized as one of the most common cancers in the world that disproportionately affects Southeast Asians and Africans. While there are therapies that possibly provide a cure, surgical removal and liver transplantation are invasive and radical options. However, even these approaches only benefit a small proportion of the total number HCC patients.
|
| 8/13/2009
3:00 AM |
|
|
The Factors Associated With The Use Of Gastric Cancer Screening Services In Korea
|
| The mortality rate associated with gastric cancer is decreasing, despite the increasing incidence in Korea. This can be explained by surgical technique development and early detection by endoscopic screening or upper gastrointestinal study. A research article published on August 7, 2009 in the World Journal of Gastroenterology addresses this problem. Although stomach cancer screening is effective for reducing mortality, it is under-utilized in Korea.
|
| 8/13/2009
3:00 AM |
|
|
For 14 Months, He Couldn't Eat Or Drink
|
| For 14 months, Daniel Steinhauer could not eat or drink, due to the side effects of throat cancer surgery and radiation. But at Loyola University Health System, Steinhauer learned how to swallow again in a therapy program that included exercising his swallowing muscles and undergoing electrical stimulation of throat muscles. Steinhauer vividly remembers his first drink -- a can of cold Diet Coke. "It was like a miracle," he said. "I could hear the harps.
|
| 8/13/2009
2:00 AM |
|
|
New Fertility Treatment Option Now Available For Cancer Patients
|
| Cancer patients who want to start a family in the future now have a new option. Montefiore's Institute for Reproductive Medicine & Health is the only site in the New York metropolitan area and one of approximately 25 sites across the country to offer a new treatment option to preserve fertility for female patients undergoing cancer treatment.
|
| 8/13/2009
1:00 AM |
|
|
First Pediatric Patient Treated With Aptocine(TM), A Novel Light-Activated Drug, In Neurofibromatosis Study
|
| Light Sciences Oncology, Inc. (LSO) announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated drug Aptocine(TM) (talaporfin sodium) in neurofibromatosis type 1 (NF-1). Investigators at the Neurofibromatosis/Neuro-Oncology Clinic of Children's Hospital of Philadelphia (CHOP) treated a pediatric patient with NF-1 and plexiform neurofibromas (PN) using Aptocine, which is also in late-stage development for solid tumors.
|
| 8/13/2009
1:00 AM |
|
|
Aspirin Use After Colorectal Cancer Diagnosis Associated With Improved Survival
|
| Men and women who were diagnosed with colorectal cancer and began regular use of aspirin had a lower risk of overall and colorectal cancer death compared to patients not using aspirin, according to a study in the August 12 issue of JAMA. Numerous prospective, observational studies demonstrate that regular aspirin use is associated with a lower risk of colorectal adenoma (a benign tumor) or cancer.
|
| 8/13/2009
12:00 AM |
|
|
Endocyte Announces Positive Results From A Phase II Clinical Study Of EC145 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
|
| Endocyte Inc., (http://www.endocyte.com/) a cancer drug discovery and development company, has announced results from a Phase II clinical study of EC145 (http://www.endocyte.com/pipeline.html) in patients with advanced non-small cell lung cancer (NSCLC). Results were presented at the 13th World Conference on Lung Cancer in San Francisco.
|
| 8/13/2009
12:00 AM |
|
